Study guide
20.3 Community Resources, Systems Navigation & Collaborative Documentation
Certified Addictions Registered Nurse - Advanced Practice CARN-AP
Track your progress as you read
Finished sections get a check mark.
1 Introduction: The CARN-AP Examination & Foundations of Advanced Addictions Practice
About the CARN-AP Examination: Blueprint, Scoring & Eligibility The Neurobiology of Addiction: Binge, Withdrawal & Preoccupation Screening, SBIRT & the ASAM Criteria Levels of Care
2 Chapter 1: Opioid Use Disorder: Assessment, Overdose Response & Methadone Maintenance
1.1 OUD Assessment, DSM-5-TR Diagnostic Criteria, and Clinical Opiate Withdrawal Scale (COWS) 1.2 Methadone Pharmacology, OTP Federal Regulations, QTc Prolongation & CYP450 Interactions 1.3 Opioid Overdose Assessment, Harm Reduction, Naloxone Formulations & Nalmefene
3 Chapter 2: Buprenorphine Protocols, Long-Acting Injectables & Naltrexone
2.1 Buprenorphine Pharmacology, Standard Office/Home Induction & Precipitated Withdrawal Management 2.2 Low-Dose Micro-Induction (Bernese Method) & Fentanyl Transition Strategies 2.3 Long-Acting Injectable Buprenorphine (Sublocade, Brixadi) & Extended-Release Naltrexone (Vivitrol)
4 Chapter 3: Alcohol Use Disorder: Neurobiology, Assessment & Acute Withdrawal
3.1 AUD Neurobiology, Epidemiology, Screening Instruments (AUDIT, AUDIT-C, CAGE) & Laboratory Biomarkers 3.2 Alcohol Withdrawal Syndrome, CIWA-Ar Protocol, Symptom-Triggered Benzodiazepine Regimens & Delirium Tremens 3.3 Wernicke-Korsakoff Syndrome, High-Dose Parenteral Thiamine Protocols & Acute Medical Complications
5 Chapter 4: Medications for Alcohol Use Disorder (MAUD)
4.1 Oral and Injectable Naltrexone for AUD: Mechanism, Prescribing Protocols & Clinical Efficacy 4.2 Acamprosate Calcium: NMDA Modulation, Renal Dosing Parameters & Abstinence Maintenance 4.3 Disulfiram and Second-Line / Off-Label MAUDs: Topiramate, Gabapentin & Baclofen
6 Chapter 5: Stimulant, Sedative-Hypnotic & Synthetic Substance Use Disorders
5.1 Stimulant Use Disorder (Cocaine & Methamphetamine): Neurotoxicity, Medical Emergencies & Evidence-Based Interventions 5.2 Sedative, Hypnotic, and Anxiolytic Disorders: Dependence Physiology, Risks & Outpatient Tapering Protocols 5.3 Emerging Synthetic Drugs: Fentanyl Analogues, Synthetic Cathinones, Cannabinoids & Xylazine-Associated Necrotic Wounds
7 Chapter 6: Tobacco and Cannabis Use Disorders: Evidence-Based Pharmacotherapy & Interventions
6.1 Tobacco Use Disorder & Nicotine Dependence: Dual NRT, Varenicline & Bupropion Prescribing Protocols 6.2 Cannabis Use Disorder, Synthetic Cannabinoids & Cannabinoid Hyperemesis Syndrome 6.3 Behavioral Therapies in Substance Use: Motivational Interviewing, CBT & Contingency Management
8 Chapter 7: Psychiatric Differential Diagnosis & Medical Mimics in Addictions
7.1 Diagnostic Formulation: Primary vs. Substance-Induced Psychiatric Disorders & The 30-Day Rule 7.2 Endocrine, Neurological, and Metabolic Mimics of Substance Intoxication and Withdrawal 7.3 Decisional Capacity, Competency, and Involuntary Commitment in Acute Addiction Practice
9 Chapter 8: Co-Occurring Psychiatric Disorders: Integrated Treatment Planning
8.1 Integrated Dual Diagnosis Treatment (IDDT) Framework & High-Prevalence Mood / Anxiety Co-Occurring Disorders 8.2 Complex Severe Mental Illness: Psychotic Disorders, Bipolar Disorder & Borderline Personality in Addictions 8.3 Trauma-Informed Care, PTSD, and Addictions: Evidence-Based Integrated Psychotherapy
10 Chapter 9: Pain Management in Substance Use Disorders & CDC 2022 Guidelines
9.1 CDC 2022 Clinical Practice Guideline for Prescribing Opioids for Chronic Pain: Individualized Assessment vs. Hard Caps 9.2 Multimodal Non-Opioid Pharmacotherapy, Interventional Modalities & Non-Pharmacological Strategies 9.3 Acute Pain Management in Patients on Maintenance MOUD (Methadone, Buprenorphine, Naltrexone)
11 Chapter 10: Perinatal Substance Use, Neonatal Abstinence & Infectious Complications
10.1 Perinatal Substance Use Disorder: ACOG/ASAM Guidelines, MOTHER Trial & Maintenance MOUD 10.2 Neonatal Abstinence Syndrome (NAS/NOWS): Finnegan Scoring vs. Eat, Sleep, Console (ESC) & Breastfeeding 10.3 Infectious Complications in People Who Inject Drugs: Viral Hepatitis, HIV, Endocarditis & PrEP/PEP
12 Chapter 11: Federal Regulations, Confidentiality & Controlled Substance Prescribing
11.1 Controlled Substances Act, DEA Registration, Schedule Classifications & MAT Act of 2023 11.2 Confidentiality of Substance Use Disorder Patient Records: 42 CFR Part 2 (2024 Final Rule) & HIPAA Harmonization 11.3 Prescription Drug Monitoring Programs (PDMP) & Urine Drug Testing (UDT) Interpretation
13 Chapter 12: APRN Scope of Practice, Ethical Foundations, Harm Reduction & Research Literacy
12.1 APRN Scope of Practice, Prescriptive Authority & Collaborative Practice Regulations 12.2 Ethical Dilemmas in Addictions Nursing: Stigma, Autonomy, Justice, and Maternal/Fetal Rights 12.3 Harm Reduction Philosophy, Syringe Service Programs, Drug Checking & Overdose Prevention 12.4 Landmark Clinical Trials & Research Literacy in Addictions Medicine
14 Chapter 13: Stimulant Use Disorder in Depth — Methamphetamine, Withdrawal, Treatment & Harm Reduction
13.1 Methamphetamine Use Disorder: Pharmacology, Medical & Psychiatric Sequelae 13.2 Stimulant Withdrawal, Craving & Contingency Management 13.3 Pharmacotherapy Research for Stimulant Use Disorder 13.4 Stimulant Harm Reduction, Overamping & Patient Education
15 Chapter 14: Medical Consequences of Alcohol Use — Liver, Heart, Cancer & Nutrition
14.1 Alcohol-Associated Liver Disease: Staging, Scoring & Management 14.2 Cardiovascular, Oncologic & Nutritional Consequences of Alcohol
16 Chapter 15: Brief Intervention, Drinking Goals & Recovery Support in Alcohol Use Disorder
15.1 Brief Intervention, Drinking Goals & Shared Decision Making in AUD 15.2 Relapse Prevention, Mutual-Help Programs & Recovery Support
17 Chapter 16: Tobacco Use Disorder in Depth — Neurobiology, Assessment & Special Populations
16.1 Nicotine Neurobiology, Epidemiology & the Tobacco Product Landscape 16.2 Tobacco Assessment & Behavioral Treatment: 5 A's, Quitlines & Incentives 16.3 Tobacco Treatment in Special Populations & Co-Occurring Disorders
18 Chapter 17: Cannabis Use Disorder in Depth — Products, Treatment & Policy
17.1 Cannabinoid Pharmacology, Potency & the Modern Product Landscape 17.2 Cannabis Use Disorder: Epidemiology, Assessment & Treatment Evidence 17.3 Medical Cannabis, Legalization Policy, Adolescent Risk & Patient Education
19 Chapter 18: Other Use Disorders — Inhalants, Hallucinogens, Process Addictions & Prescription/OTC Misuse
18.1 Inhalant Use Disorder: Volatile Solvents, Nitrous Oxide & Alkyl Nitrites 18.2 Hallucinogens & Dissociatives: Classic Psychedelics, PCP, Ketamine & HPPD 18.3 Process (Behavioral) Addictions: Gambling Disorder, Gaming & Compulsive Behaviors 18.4 Prescription & Over-the-Counter Substance Misuse: Opioids, Stimulants, Kratom & DXM
20 Chapter 19: Educating Patients, Families & the Public (CARN-AP Activity Area III)
19.1 Designing Health Teaching: Literacy, Readiness, Culture & Teach-Back 19.2 Medication Education, Informed Consent & Informed Refusal 19.3 Family & Support-System Education: CRAFT, Al-Anon & Overdose Prevention Teaching 19.4 Public, Professional & Anticipatory Guidance: Prevention and Advocacy Teaching
21 Chapter 20: Consultation, Collaboration & Care Coordination (CARN-AP Activity Area IV)
20.1 The APRN Consultation Process & Communicating Recommendations 20.2 Interprofessional Collaboration, Care Coordination & Transitions of Care 20.3 Community Resources, Systems Navigation & Collaborative Documentation
22 Chapter 21: Quality Improvement, Evidence & Leadership in Addictions Nursing (CARN-AP Activity Area V)
21.1 Outcome Measurement & Continuous Quality Improvement in Addictions Care 21.2 Policy Advocacy, Leadership & the Determinants of Addiction
20.3 Community Resources, Systems Navigation & Collaborative Documentation
Key Takeaways Explain This Topic AI
Housing instability, transportation and benefits interruption are among the most common practical reasons treatment plans fail, and addressing them is clinical work rather than an adjunct.
Recovery housing quality varies enormously, and APRNs should verify that a residence permits medication for opioid use disorder before referring a patient who takes it.
Medicaid coverage lapses during incarceration and hospitalization are a leading cause of post-transition treatment interruption, and reinstatement should be arranged before release.
Documenting the rationale for a change, not just the change itself, is the highest-rated documentation activity in the CARN-AP practice analysis.
Collaborative documentation written with the patient during the visit improves accuracy, engagement and the patient's understanding of the plan.
Last updated: September 2026
20.3 Community Resources, Systems Navigation & Collaborative Documentation
Quick Answer: The practice analysis rates "facilitates the utilization of systems, organizations, and community resources when implementing the plan" (index 8.84) and "documents communication, rationales for changes, and collaborative discussions in the plan of care to improve outcomes" (10.14) within Activity Area IV. The practical content is housing, transportation, benefits, legal navigation and recovery support , plus documentation that records why a decision was made so the plan survives the next handoff.
1. The Barriers That Actually Break Plans
Barrier Typical failure mode APRN countermeasure
Housing Patient discharged to a shelter that requires daytime exit and bans medication storage Verify the residence permits medication; document the storage plan; prioritize recovery-housing placement that accepts MOUD
Transportation Patient cannot reach a daily-dosing OTP Medicaid non-emergency medical transportation; bus passes; telehealth where permitted; transfer to a nearer program
Benefits Medicaid suspended during incarceration or lapsed during hospitalization Reinstatement application before release; hospital financial counseling; patient assistance programs
Identification No ID means no pharmacy pickup, no shelter bed, no job Connect to programs that replace birth certificates and state IDs
Employment Daily dosing conflicts with a work shift Advocate for take-home dosing; document medical necessity; explore extended-release products
Child welfare involvement Fear of reporting suppresses disclosure Explain clearly what is and is not reportable in your jurisdiction; Plans of Safe Care under CAPTA are a support mechanism, not automatically a removal mechanism
Legal supervision Probation conditions that prohibit "narcotics" have been applied to buprenorphine Provide written clinical documentation; ADA protections have been applied to MOUD in several enforcement actions
2. Vetting Recovery Housing
Recovery residences range from well-run, accredited homes to unregulated operations. Before referring, verify:
Does it permit medication for opioid use disorder? A residence that requires a taper off buprenorphine is unsafe for a patient who takes it, and this is the single most important question.
Is it accredited by a state affiliate of a national recovery housing standard body?
What are the discharge rules? Immediate expulsion for a single positive test puts the patient on the street at the moment of highest risk.
Is naloxone on site , and is staff trained to use it?
What are the fees , and is there any financial relationship between the referring entity and the residence?
3. Telehealth in Addictions Practice
Telehealth substantially expands access for rural and transportation-limited patients, and buprenorphine initiation by telehealth has been permitted under evolving federal rules. Because those rules have changed repeatedly, the durable exam-relevant principles are:
Verify the current federal rule and your state law before initiating by telehealth , including whether audio-only is permitted.
State licensure follows the patient's location , not the clinician's.
Methadone for opioid use disorder still requires an OTP regardless of telehealth rules.
Document the modality , the patient's location, and the identity verification performed.
4. Documentation That Carries the Plan Forward
The highest-rated documentation activity specifies three things: communication , rationales for changes , and collaborative discussions . Most notes record only the decision.
Decision-only note Note that carries the rationale
"Increased buprenorphine to 20 mg daily." "Increased buprenorphine to 20 mg daily because the patient reports craving returning by 4 p.m. and a positive fentanyl result on 9/3. Discussed split dosing versus total dose increase; patient preferred a single morning dose for work reasons. Will reassess in 1 week; if craving persists, will trial split dosing before further escalation."
"Patient declined naltrexone." "Patient declined extended-release naltrexone, citing a friend's severe reaction. Explained the required 7 to 10 opioid-free days and what precipitated withdrawal involves; she remained hesitant. Offered buprenorphine as an alternative, which she accepted. Door left open for naltrexone if her preference changes."
The second version survives a handoff, prevents a colleague from repeating a failed approach, and demonstrates the shared decision making the blueprint requires.
5. Collaborative Documentation
Collaborative documentation (sometimes called concurrent documentation) means writing the note with the patient during the visit , reading the plan aloud and inviting correction.
- Benefit Mechanism
- Accuracy The patient corrects errors in real time
- Engagement The patient hears their own goal reflected back in their own words
- Comprehension Reading the plan aloud functions as a teach-back opportunity
- Transparency Reduces the suspicion patients bring to addiction records, where they expect surveillance
- Efficiency Eliminates after-hours charting backlog
With open-notes access now standard, patients read these records anyway. Writing them collaboratively and in non-stigmatizing language is both a clinical and a therapeutic act.
6. A Short Navigation Checklist Before Any Discharge
Where will the patient sleep tonight, and does that place allow the medication?
Does the patient have the medication in hand or a prescription that can be filled today?
Does the patient have naloxone in hand?
Is the next appointment scheduled, with date, time, address, and a way to get there?
Is insurance active, and if not, has reinstatement been started?
Does the patient have a phone that will still work next week?
Does one named clinician own each controlled substance?
Does the receiving clinician know the patient is coming?